OBIO · Orchestra BioMed Holdings Inc
United States · RS rating 87 · As of 2026-11-03
| Price | 5.56 USD |
|---|---|
| 1-day change | -2.3% |
| RS rating (overall / 1M / 3M / 12M) | 87 / 39 / 93 / 82 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 39 / 69 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -15.2% |
| Sales growth Q/Q | +3490.8% |
| Distance from 52-week high | +12.4% |
| Market cap (USD) | $242.9M |